Please type a plus sign (+) inside this box	 +	

PTO/SB/05 (11-00) Approved for use through 10/31/2002, OMB 0651-0032

Pt Box/sed

U..S. Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number 38-21(51892)B Attorney Docket No. UTILITY Bougri, Oleg V. First Inventor PATENT APPLICATION Ø NUCLEIC ACID MOLECULES AND OTHER MOLECULES Title TRANSMITTAL ASSOCIATED WITH PLANTS (Only for new nonprovisional applications under 37 CFR 1.53 (b)) EK089244633US Express Mail Label No. **Assistant Commissioner for Patents** APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) 7. Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status. (if applicable, all necessary) X Specification [Total Pages Computer Readable Form (CFR) (preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention - Cross References to Related Applications CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R and D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention Statement verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet\_document(s)) 9. - Claim(s) - Abstract of the Disclosure 37 CFR 3.73(b) Statement Power of 10. Attorney (when there is an assignee) Drawing(s) (35 USC 113) [Total Sheets English Translation Document (if applicable) 20 Information Disclosure Copies of IDS Total Pages Oath or Declaration 12. Statement (IDS)/PTO-1449 Citations Newly executed (original or copy) Preliminary Amendment 13. Copy from a prior application (37 CFR 1.63(d)) Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 17 completed 14. (should be specifically itemized) Certified Copy of Priority Document (s) DELETION OF INVENTOR(S) 15. (if foreign priority is claimed) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Request and Certification under 35 U.S.C. 122 1.63(d)(2) and 1.33(b). 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: of prior application No: Continuation Divisional Continuation-in-part (CIP) Group/Art Unit. Prior Application Information. Examiner For CONTINUATION OR DIVISIONAL APPS ONLY. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Correspondence address below Ansert Customer No. or attach Bar Code Customer Number or Bar Code Label Lawrence M. Lavin, Jr. Name Patent Department, E2NA; Monsanto Company 800 N. Lindbergh Boulevard Address Missouri ZIP CODE 63167 City St. Louis State (314) 694-1671 USA (314) 694-3602  $\overline{FAX}$ Telephone Country 30768 Name (Print/Type) Lawrence M. Lavin, Jr. Registration No. (Attorney/Agent)

Burden Hour Statement This form is estimated to take 2 hours to complete Time will vary depending pon the needs of the individual cases. Any comments on the amount of time you required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

(Reg. No. 41422)

Date:

Jr.

Signature

U..S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<u> </u>			<u>.</u>			mplete if Known		
FEE TRANSMITTAL				n Num	ber	-		
for FY 2001			ig Dat					
				ed Inve	entor	Bou	ugri, Oleg V.	
Patent fee are subject to annual revision.				Name				
AL AMOUNT OF PAYMENT (\$) 710			ıp Art	Docket	No	38	B-21(51892)B	
		Atto	iney i	JOCKET	140.	30	J-21(010)2)D	
METHOD OF PAYMENT (check one)								
1. X The Commissioner is hereby authorized to charge	3. AD	DITIO						
indicated fees and credit any overpayments to:  Deposit	Large Fee	Fee	Small Fee	Fee		Fee Description	l.	Fee Paid
Account Number 13-4125	Code 105	(\$) 130	Code 205	(\$) 65	Surcharge	- late filing fee or oath		0
Deposit							a fan an aavan sha	
Account Name	127	50	227	25		e - late provisional filing	g lee of cover she	
X Charge Any Additional Fee Required	139	130	139	130	_	ish specification		0
under 37 CFR 1.16 and 1.17	147	2,520	147	2,520	For filing a	request for ex part reex	xamination	0
Applicant claims small entity status.	112	920*	112	1,840*	Requesting	publication of SIR price	or to Examiner acti	ion 0
See 37 CFR 1.27	113	1,840*	113	1,840*	Requesting	publication of SIR afte	er Examiner action	0
2. Payment Enclosed:	115	110	215	55	Extension	n for reply within first m	nonth	0
Check Credit card Order Other	116	380	216	190	Extension	for reply within second	d month	0
FEE CALCULATION	117	870	217	435	Extension	n for reply within third r	month	0
1. BASIC FILING FEE	118	1,360	218	680	Extension	ı for reply within fourth	month	0
Earge Entity Small Entity	128	1,850	228	925		n for reply within fifth n		0
Fee Fee Fee Fee description  Gode (\$) Code (\$)	119	300	219	150	Notice of	• •		0
101 710 201 355 Utility filing fee <b>710</b>						••	,	<u></u>
106 320 206 160 Design filing fee	120	300	220	150		rief in support of an app	pear	0
107 490 207 243 Plant filing fee	121	260	221	150	Request f	for Oral hearing		0
108 710 208 355 Reissue filing fee	138	1,510	138	1,510	Petition to	institute a public use p	roceeding	0
114 150 214 75 Provisional filing fee	140	110	240	55	Petition	to revive - unavoidable		0
100 710 200 355 Relisate liming fee 114 150 214 75 Provisional filing fee SUBTOTAL (1) (\$) 710	141	1,210	241	605	Petition t	o revive - unintentional		0
2. EXTRA CLAIM FEES	142	1,210	242	605	Utility is:	sue fee (or reissue)		0
Extra Claims below Fee Paid	143	430	243	215	Design i	ssue fee		0
Total=Claims 9 -20** = -11 X 18 = 0	144	430	243	215	Plant iss	ue fee		0
Independent Claims $3 - 3** = 0 X 80 = 0$	122	130	122	130	Petitions	to commissioner		0
Multiple Dependent $270 = 0$	123	50	123	50		ing under 37 CFR 1.17(	(a)	0
** or number previously paid, if greater; For reissues, see below	Ì					ion of information Disc		0
Large Entity Small Entity Fee Fee Fee Fee Fee description	126	240	126	240				
Code (\$) Code (\$)	581	40	581	40	Record (times	ling each patent assignn number of properties)	nent per property	0
103 18 203 9 Claims in excess of 20	146	690	246	345	Filing a	submission after final r FR §1 129(a))	rejection	0
102 80 202 40 Independent claims in excess of 3	149	690	249	345	For each	additional invention to	be examined	0
104 270 204 135 Multiple dependent claims, if not paid					(37 C	FR §1.129(b))		0
109 80 209 40 ** Reissue independent claims over original patent	179	690	279	345	kequest	for continued Examinat	uon (RCE)	U
110 18 210 9 ** Reissue claims in excess of 20	169	900	169	900	Request	for expedited examinate	ion	0
and over original patent	Other	fee (spec	ify)			enon approaction		
SUBIOTAL (2) (3)								
** or number previously paid, if greater; For reissues, see abive *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)								
SUBMITTED BY							Complete	(if applicabl
Name (Print/Type) Lawrence M. Lavin, Jr.	Re	egistrati	on No.	(Attorne	ry/Agent)	30768	Telephone (	314) 694-360
Signature Lawrence M. Lavin Jr.	5. J;	nu S	Zh	n (Re	g. No. 4	-1.4-2-2)	Date: <	2/18/20
WARNING: Information on this form of	7				<del>/</del>	, , ,	Mrs /	

Docket No. 38-21(51892)B Inventors: Oleg V. Bougri et al.

Page 1 of 3

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Oleg V. Bougri et al.

Appln. No.: To Be Assigned

Filed:

For:

Nucleic Acid Molecules and Other

Molecules Associated With Plants

Art Unit:

To Be Assigned

Examiner:

To Be Assigned

Atty. Docket: 38-21(51892)B

I hereby verify this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No. EK089244633US on the date indicated and is addressed to: Commissioner for Patents, Washington, D.C. 20231

Jian S. Zhou

Registration No. 41, 422

Date: April 18, 200/

TRANSMITTAL OF NON-PROVISIONAL PATENT APPLICATION

Commissioner for Patents

**Box Patent Application** 

Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the complete patent application of:

**Nucleic Acid Molecules and Other Molecules Associated with Plants** 

Inventors: Oleg V. Bougri

Joseph R. Byrum

Robert C. De La Pena



# Thomas J. La Rosa Hridayabhiranjan Shukla

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. Utility Patent Application Transmittal (PTO/SB/05);
- 2. Form PTO/SB/17 (in duplicate);
- 3. U.S. Utility Patent Application entitled:

## Nucleic Acid Molecules and Other Molecules Associated with Plants

and naming as inventors:

Oleg V. BOUGRI, Joseph R. BYRUM, Robert C. DE LA PENA, Thomas J. LA ROSA and Hridayabhiranjan SHUKLA

the application consisting of:

- a. A specification containing:
  - (i) 68 pages of a description prior to the claims;
  - (ii) \_\_\_\_\_ page of claims (9 claims); and
  - (iii) a one (1) page abstract;
- 4. The computer readable form (CRF) containing the sequence listing information;
- 5. 2 CD-Rs (Copy 1, Copy 2) containing the Sequence listing;
- 6. Statement regarding Sequence Submission;
- 7. Combined Declaration and Power of Attorney, executed by inventor Oleg V. Bougri (4 pages);
- Combined Declaration and Power of Attorney, executed by inventor Joseph R.
   Byrum (4 pages);

9. Combined Declaration and Power of Attorney, executed by inventor Robert C. De

La Pena (4 pages);

10. Combined Declaration and Power of Attorney, executed by inventor Thomas J. La

Rosa (4 pages);

11. Combined Declaration and Power of Attorney, executed by inventor

Hridayabhiranjan Shukla (4 pages);

12. Form PTO/SB/35;

13. An Information Disclosure Statement;

14. Form PTO-1449 (1 page), with 8 accompanying documents; and

15. Two (2) return postcards

It is respectfully requested that the two attached prepaid postcards be stamped with the filing date and unofficial application number and returned as soon as possible.

Respectfully submitted,

Lawrence M. Lavin, Jr., Esq (Reg. No. 30,768)

Jian S. Zhou (Reg. No. 41,422)

Enclosures

Date: April 18, 200/

Patent Department, E2NA

Monsanto Company

800 N. Lindbergh Boulevard

St. Louis, MO 63167

Tel: 636-694-3602 Fax: 636-694-1671

U..S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor		Oleg V. Bougri		
Title	tle NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH PLANTS			
Attorney Docket No.		38-21(51892)B		

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

April 18, 2001

Signature

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing.** 

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant mustnotify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).

# Hard to the control of the control o

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Oleg V. Bougri et al.

Art Unit:

To be assigned

Appln. No.: To Be Assigned

Examiner:

To be assigned

Filed:

Atty. Docket: 38-21(51892)B

For:

Nucleic Acid Molecules And Other Molecules Associated With Plants

I hereby verify this Statement together with the patent application referred to above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No.EK089244633US on the date indicated and is addressed to: Commissioner for Patents, Washington, D.C. 20231

Jian S. Zhou

Registration No. 41, 422

**Statement Regarding Sequence Submission** 

**Assistant Commissioner for Patents** 

Washington, DC 20231

**Box Patent Application** 

Sir:

In accordance with 37 C.F.R. § 1.821(f), the sequence listing information recorded in computer readable form (CRF) submitted herewith in the above-mentioned application is identical to the written sequence listing on CD-R (2 copies).

Respectfully submitted,

Jian S. Zhou

(Reg. No. 41,422)

Date: April 18, 200/

Patent Department, E2NA, Monsanto Company

800 N. Lindbergh Blvd.

St. Louis, MO 63167 Tel: (314) 694-3602 Fax: (314) 694-1671